Orchestra BioMed Holdings, Inc.

Contributing Author

Recent Articles by Orchestra BioMed Holdings, Inc.

May-12	Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates OBIO GlobeNewswire
May-12	Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 OBIO GlobeNewswire
May-06	Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement OBIO GlobeNewswire
May-06	Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement OBIO GlobeNewswire
Apr-30	FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy OBIO +5.00% GlobeNewswire
Apr-23	Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 OBIO GlobeNewswire
Mar-12	Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update OBIO GlobeNewswire
Mar-03	Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT OBIO GlobeNewswire
Feb-19	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences OBIO GlobeNewswire
Feb-13	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OBIO GlobeNewswire
Jan-12	Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics OBIO GlobeNewswire
Dec-08	Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting OBIO GlobeNewswire
Nov-26	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OBIO GlobeNewswire
Nov-11	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences OBIO +8.47% GlobeNewswire
Nov-10	Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates OBIO GlobeNewswire
Nov-03	Orchestra BioMed to Host Business Update Call on November 12, 2025 OBIO GlobeNewswire
Oct-28	Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements OBIO GlobeNewswire
Oct-27	Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial OBIO GlobeNewswire
Oct-09	Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit OBIO GlobeNewswire
Sep-04	Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout OBIO GlobeNewswire
Aug-26	Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology OBIO +15.38% GlobeNewswire
Aug-14	Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction OBIO GlobeNewswire
Aug-12	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates OBIO +7.94% GlobeNewswire
Aug-08	Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility OBIO GlobeNewswire
Aug-05	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings OBIO GlobeNewswire
Aug-01	Orchestra BioMed Announces Pricing of $40 Million Public Offering OBIO -20.26% GlobeNewswire
Jul-31	Orchestra BioMed Announces Proposed Public Offering OBIO GlobeNewswire
Jul-31	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed OBIO -20.26% OBIO GlobeNewswire
Jun-18	Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 OBIO -11.01% GlobeNewswire
May-12	Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones OBIO +10.94% OBIO GlobeNewswire
May-07	Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure OBIO GlobeNewswire

Orchestra BioMed Holdings, Inc.

Recent Articles by Orchestra BioMed Holdings, Inc.

Upgrade your Finviz experience